



EMORY UNIVERSITY SCHOOL OF MEDICINE

DEPARTMENT OF PSYCHIATRY AND BEHAVIORAL SCIENCES

1639 Pierce Drive, Suite 4000

Atlanta, Georgia 30322


Charles B. Nemeroff, MD, PhD
Reunette W. Harris Professor and Chairman

WMB Bldg.

FAX [REDACTED]

e-mail: [REDACTED]@emory.edu

May 22, 2000



Confidential

Thomas J. Lawley, M.D.
Dean
Emory School of Medicine
3rd Floor WHSCAB

Dear Dr. Lawley:

This is in follow-up to your letter of May 15, 2000 and our meeting last week to discuss my consulting activities. As I indicated to you, there was a clear misunderstanding concerning the 19 activities listed by me in terms of consulting agreements. I was overly inclusive, as I think all faculty should be, in terms of these agreements and therefore, included all of my work on behalf of patient advocacy groups that is, of course, volunteer work. There was also a clear misunderstanding as to the time required by me to serve on one or another of these advisory boards. In the space below, I attempt of clarify these issues.

First, the four organizations at the end of my list in my letter to you dated December 20, 1999 are all patient advocacy groups. They include the American Foundation for Suicide Prevention, the National Depression and Manic-Depression Disorders Association, the Anxiety Disorders Association of America and the American Psychiatric Association Research Institute - Board of Directors. It is a great honor for me to be on the Board of Directors of three of four of these patient organizations, and a member of the Scientific Advisory Board of the fourth. No other psychiatry chair in the country has been honored in this way and the recognition of mental illness is, after all, one of our main goals of our specialty. I wish to emphasize that none of this work is funded with any honoraria or consulting fees. Of the remaining 15 organizations listed, I no longer chair the Solvay Pharmaceutical Advisory Board, but serve as a member. It, like all of the boards I will describe below, invariably meets on weekends and this does not detract from my Emory time. As a member of the Solvay Advisory Board, I would spend a maximum of two days per year in those meetings.


Of the others, I chair the Smith-Kline Beecham Pharmaceuticals Advisory Board. This, too, meets twice a year, always on weekends. The Eli Lilly Board of which I am a member, meets twice per year, also on weekends. The Janssen Pharmaceutical Advisory Board meets once or twice per year, but usually during national meetings that I must attend for other reasons. I am no

longer a member of the Pharmacia-Upjohn Psychiatry Advisory Board. I do chair the Astra-Zeneca Board and that, too, meets on weekends. I serve as a consultant to Merck and there is only one meeting per year in that capacity. The Bristol-Myers-Squibb Psychiatry Advisory Board meets twice a year, almost always on weekends. The Wyeth-Ayerst Advisory Board which I chair meets twice per year usually on the weekends or at national weekends. I no longer on the Pfizer Pharmaceutical Advisory Board. I do chair one of the Forrest Lab Advisory Boards, and they also meet twice per year and usually on the weekends. I am a member of the Organon Advisory Board, it has not met in more than a year. The George West Mental Health Foundation is a non-profit organization led by Charles and Mark West and they are responsible for Skyland Trail, an affiliate of our department and university. The Board of Directors are not compensated. Finally, I serve on two Biotech Advisory Boards: Corcept, which has never met, and Neurocrine Biosciences which meets once a year.

Surely you remember that Smith-Kline Beecham Pharmaceuticals donated an endowed chair to the department and that there is some reasonable likelihood that Janssen Pharmaceuticals will do so as well. In addition, Wyeth-Ayerst Pharmaceuticals has funded a Research Career Development Award program in the department, and I have asked both AstraZeneca Pharmaceuticals and Bristol-Meyers Squibb to do the same. Part of the rationale for their funding our faculty in such a manner would be my service on these boards. Of course, I understand your concern about my time away from Emory in the past year. This is partly due to personal circumstances in my life as well as professional obligations. I am the only Chair of Psychiatry, I believe in the nation, who serves on two national advisory councils: NIMH and NASA. I also serve on the External Advisory Board for the Max Planck Institute in Munich. Although these obligations do take time, these activities are useful for our faculty in a number of ways both collaborative and otherwise. Without the funds I have raised from the pharmaceutical company in the form of unrestricted gifts, I could not come close to maintaining a revenue neutral university department much less a clinic section that does not lose considerable sums of money.

I am trying to balance my various responsibilities and considering the fact that I am Principal Investigator of a Center Grant and two R01s from NIH, it is no small task. I appreciate your protecting me from outside forces and our frank discussion was exactly the tenor necessary for us to work well together and get through these complex issues. If you have any further questions concerning my external involvement with one or another of these entities, please do not hesitate to contact me.

Sincerely,

A handwritten signature in black ink, appearing to read 'Charles B. Nemeroff', with a long, sweeping horizontal line extending to the right from the end of the signature.

Charles B. Nemeroff, M.D., Ph.D.
Reunette W. Harris Professor and Chair